Drug details

Retevmo (selpercatinib capsules)

type of Antineoplastics, VEGF Inhibitor, RET Kinase Inhibitors

Retevmo (selpercatinib) is a kinase inhibitor used to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

This drug may have the following side effects:
  • rash,
  • diarrhea,
  • dry mouth,
  • fatigue,
  • constipation
  • decreased platelets,
  • increased creatinine,
  • high blood pressure (hypertension),
  • fluid retention (edema),
  • increased alkaline phosphatase,
  • decreased leukocytes,
  • decreased calcium,
  • decreased albumin,
  • decreased sodium, and
  • increased aspartate aminotransferase (AST),
  • increased alanine aminotransferase (ALT),
  • increased blood sugar (glucose),
  • increased total cholesterol,
The following drugs are related to Retevmo, either as a replacement or used together:
  • Alimta (pemetrexed)
  • Alymsys (bevacizumab-maly injection)
  • Tecentriq (atezolizumab injection)
  • Avastin (bevacizumab)
  • Zirabev (bevacizumab-bvzr injection)
  • Tabrecta (capmatinib tablets)
  • Zykadia (ceritinib hard-gelatin capsules)
  • Xalkori (crizotinib)
  • Cyramza (ramucirumab solution for intravenous infusion)
  • Tafinlar (dabrafenib capsules)
  • Vizimpro (dacomitinib)
  • Taxotere (docetaxel for injection)
  • Imfinzi (durvalumab injection)
  • Rozlytrek (entrectinib capsules)
  • Tarceva (erlotinib)
  • Exkivity (mobocertinib capsules)
  • Iressa (gefitinib)
  • Gemzar (gemcitabine hcl)
  • Infugem (gemcitabine in sodium chloride injection)
  • Keytruda (pembrolizumab for injection)
  • Mekinist (trametinib tablets)
  • Portrazza (necitumumab intravenous injection)
  • Opdivo (nivolumab injection)
  • Tagrisso (osimertinib tablets)